作者:Tatjana Kovacevic、Milan Mesic、Amir Avdagic、Miroslav Zegarac
DOI:10.1016/j.tetlet.2018.10.026
日期:2018.11
Afatinib (BIBW2992) is the anticancer drug developed by Boehringer Ingelheim. This work is reporting the synthesis of the afatinib using a new route by Ullmann-Goldberg reaction from corresponding 4-anilinoquinazoline iodide as the last step in the synthesis. This route was not described previously and it could be used for synthesis of afatinib analogues.
阿法替尼(BIBW2992)是勃林格殷格翰公司开发的抗癌药物。这项工作报告了通过Ullmann-Goldberg反应从相应的4-苯胺基喹唑啉碘化物通过Ullmann-Goldberg反应的新路线合成afatinib的最后一步。该路线先前未作描述,可用于合成阿法替尼类似物。